CSF2 and neoplasm: It has been shown that GM-CSF pretreatment led to an increase in the numbers of circulating myeloid DCs, proliferative CD4+ and CD8+ T cells, recruitment of CD8+ T cells to the tumor and a decrease in the numbers of myeloid-derived suppressor cells (MDSCs) [181,182].